Skip to main content
Top
Published in: Clinical Rheumatology 10/2018

01-10-2018 | Original Article

Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in Behçet’s disease: which and when to use?

Authors: Marwa Hammad, Omaima Zakaria Shehata, Shaimaa Mohamed Abdel-Latif, Amany Mohamed Mohiey El-Din

Published in: Clinical Rheumatology | Issue 10/2018

Login to get access

Abstract

Behçet’s disease (BD) is an uncommon autoimmune/autoinflammatory disease. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were investigated in many diseases as a marker of inflammation. In this study, we investigated NLR and PLR in patients with BD as a marker of disease activity and its association with different clinical manifestations. The study included 23 BD patients; their mean age was (32.5 ± 6.76) and M:F ratio was 16:7. Complete blood picture was done for all patients. NLR and PLR were compared in both active and inactive BD patients and its relation with different clinical manifestations was assessed. NLR was higher in active BD patients than in inactive BD patients (P < 0.01). Although both NLR and PLR were correlated with Behçet’s Disease Current Activity Form (BDCAF), the correlation of NLR with BDCAF was much stronger than that of PLR. NLR was associated with some mucocutaneous lesions. Both NLR and PLR were associated with articular and GIT manifestations, but also NLR showed more significant results. In our studied patients, both NLR and PLR were not informative about any ongoing ocular activity (P > 0.05). Both ratios were not affected by the presence of neurologic deficits nor previous vascular events (P > 0.05). NLR was superior to PLR as an indicator of disease activity. NLR was closely related to skin manifestations while PLR was not. In our study, both were not considered reliable in representing ocular activity.
Literature
1.
go back to reference De Chambrun MP, Wechsler B, Geri G et al (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 11(10):687–698CrossRef De Chambrun MP, Wechsler B, Geri G et al (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 11(10):687–698CrossRef
2.
go back to reference Davatchi F, AssaadKhalil S, Calamia KT et al (2014) The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28(3):338–347CrossRef Davatchi F, AssaadKhalil S, Calamia KT et al (2014) The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28(3):338–347CrossRef
3.
go back to reference Janeway CA Jr, Travers P, Walport M et al (eds) (2001) Autoimmune responses are directed against selfantigens. Immunobiology: the immune system in health and disease, 5th edn. Garland Science, New York Janeway CA Jr, Travers P, Walport M et al (eds) (2001) Autoimmune responses are directed against selfantigens. Immunobiology: the immune system in health and disease, 5th edn. Garland Science, New York
4.
go back to reference Bhat T, Teli S, Rijal J et al (2011) Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther 11(1):55–59CrossRef Bhat T, Teli S, Rijal J et al (2011) Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther 11(1):55–59CrossRef
5.
go back to reference Alexander NI (2016) Reference values of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in healthy adults in north Central Nigeria. J Blood Lymph 6:143 Alexander NI (2016) Reference values of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in healthy adults in north Central Nigeria. J Blood Lymph 6:143
6.
go back to reference Macey M, Hagi-Pavli E, Stewart J, Wallace GR, Stanford M, Shirlaw P, Fortune F (2011) Age, gender and disease-related platelet and neutrophil activation ex vivo in whole blood samples from patients with Behçet’s disease. Rheumatology 50(10):1849–1859CrossRefPubMed Macey M, Hagi-Pavli E, Stewart J, Wallace GR, Stanford M, Shirlaw P, Fortune F (2011) Age, gender and disease-related platelet and neutrophil activation ex vivo in whole blood samples from patients with Behçet’s disease. Rheumatology 50(10):1849–1859CrossRefPubMed
7.
go back to reference Yuksel M, Yildiz A, Oylumlu M, Turkcu FM, Bilik MZ, Ekinci A, Elbey B, Tekbas E, Alan S (2016) Novel markers of endothelial dysfunction and inflammation in Behçet’s disease patients with ocular involvement: epicardial fat thickness, carotid intima media thickness, serum ADMA level, and neutrophil-to-lymphocyte ratio. Clin Rheumatol 35(3):701–708CrossRefPubMed Yuksel M, Yildiz A, Oylumlu M, Turkcu FM, Bilik MZ, Ekinci A, Elbey B, Tekbas E, Alan S (2016) Novel markers of endothelial dysfunction and inflammation in Behçet’s disease patients with ocular involvement: epicardial fat thickness, carotid intima media thickness, serum ADMA level, and neutrophil-to-lymphocyte ratio. Clin Rheumatol 35(3):701–708CrossRefPubMed
8.
go back to reference Koseoglu HI, Altunkas F, Doruk S et al (2015) Platelet-lymphocyte ratio is an independent predictor for cardiovascular disease in obstructive sleep apnea syndrome. J Thromb Thrombolysis 39:179–185CrossRefPubMed Koseoglu HI, Altunkas F, Doruk S et al (2015) Platelet-lymphocyte ratio is an independent predictor for cardiovascular disease in obstructive sleep apnea syndrome. J Thromb Thrombolysis 39:179–185CrossRefPubMed
9.
go back to reference Koiwa M, Goto S, Takahashi K et al (2016) Neutrophil/lymphocyte ratio in patients with rheumatoid arthritis treated with biological agents. J Nippon Med Sch 83(3):122–123CrossRef Koiwa M, Goto S, Takahashi K et al (2016) Neutrophil/lymphocyte ratio in patients with rheumatoid arthritis treated with biological agents. J Nippon Med Sch 83(3):122–123CrossRef
10.
go back to reference Wu Y, Chen Y, Chen L et al (2016) Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus. Int Immunopharmacol 36:94–99CrossRefPubMed Wu Y, Chen Y, Chen L et al (2016) Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus. Int Immunopharmacol 36:94–99CrossRefPubMed
11.
go back to reference Li X, Chen ZH, Xing YF, Wang TT, Wu DH, Wen JY, Chen J, Lin Q, Dong M, Wei L, Ruan DY, Lin ZX, Wu XY, Ma XK (2015) Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumour Biol 36:2263–2269CrossRefPubMed Li X, Chen ZH, Xing YF, Wang TT, Wu DH, Wen JY, Chen J, Lin Q, Dong M, Wei L, Ruan DY, Lin ZX, Wu XY, Ma XK (2015) Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumour Biol 36:2263–2269CrossRefPubMed
12.
go back to reference Racz JM, Cleghorn MC, Jimenez MC et al (2014) Predictive ability of blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in gastrointestinal stromal tumors. Ann Surg Oncol 22:2343–2350CrossRefPubMed Racz JM, Cleghorn MC, Jimenez MC et al (2014) Predictive ability of blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in gastrointestinal stromal tumors. Ann Surg Oncol 22:2343–2350CrossRefPubMed
13.
go back to reference Balta S, Balta I, Ӧztürk C et al (2014) Neutrophil lymphocyte ratio in patients with Behçet’s disease and its association with carotid intimaemedia thickness. Am J Cardiol 113:7e11 Balta S, Balta I, Ӧztürk C et al (2014) Neutrophil lymphocyte ratio in patients with Behçet’s disease and its association with carotid intimaemedia thickness. Am J Cardiol 113:7e11
14.
go back to reference Ozturk C, Balta S, Balta I, Demirkol S, Celik T, Turker T, Iyisoy A, Eksioglu M (2015) Neutrophil lymphocyte ratio and carotid-intima media thickness in patients with Behçet disease without cardiovascular involvement. Angiology 66:291e6 Ozturk C, Balta S, Balta I, Demirkol S, Celik T, Turker T, Iyisoy A, Eksioglu M (2015) Neutrophil lymphocyte ratio and carotid-intima media thickness in patients with Behçet disease without cardiovascular involvement. Angiology 66:291e6
15.
go back to reference Alan S, Tuna S, Türkoğlu EB (2015) The relation of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume with the presence and severity of Behçet’s syndrome. Kaohsiung J Med Sci 31:626e631 Alan S, Tuna S, Türkoğlu EB (2015) The relation of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume with the presence and severity of Behçet’s syndrome. Kaohsiung J Med Sci 31:626e631
16.
go back to reference Avci A, Avci D, Erden F et al (2017) Can we use the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume values for the diagnosis of anterior uveitis in patients with Behcet’s disease? Ther Clin Risk Manag 13:881–886CrossRefPubMedPubMedCentral Avci A, Avci D, Erden F et al (2017) Can we use the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume values for the diagnosis of anterior uveitis in patients with Behcet’s disease? Ther Clin Risk Manag 13:881–886CrossRefPubMedPubMedCentral
17.
go back to reference Erden F, Karagoz H, Avci A et al (2017) Which one is best? Platelet/lymphocyte ratio, neutrophil/lymphocyte ratio or both in determining deep venous thrombosis in Behcet’s disease? Biomed Res 28(12):5304–5309 Erden F, Karagoz H, Avci A et al (2017) Which one is best? Platelet/lymphocyte ratio, neutrophil/lymphocyte ratio or both in determining deep venous thrombosis in Behcet’s disease? Biomed Res 28(12):5304–5309
18.
go back to reference Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 38:728–733CrossRef Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 38:728–733CrossRef
19.
go back to reference Neves FD, Caldas CAM, Medeiros DMD et al (2009) Cross-cultural adaptation of simplified version (s) of Behçet's Disease Current Activity Form (BDCAF) and comparison between two different instruments with Brazilian versions for evaluating Behçet's Disease Activity: BR-BDCAF and BR-BDCAF (s). Rev Bras Reumatol 49(1):20–31CrossRef Neves FD, Caldas CAM, Medeiros DMD et al (2009) Cross-cultural adaptation of simplified version (s) of Behçet's Disease Current Activity Form (BDCAF) and comparison between two different instruments with Brazilian versions for evaluating Behçet's Disease Activity: BR-BDCAF and BR-BDCAF (s). Rev Bras Reumatol 49(1):20–31CrossRef
20.
go back to reference Balta S, Balta I, Demirkol S, Ozturk C, Demir M (2014) Endothelial function and Behçet disease. Angiology 65(8):657–659. 3CrossRefPubMed Balta S, Balta I, Demirkol S, Ozturk C, Demir M (2014) Endothelial function and Behçet disease. Angiology 65(8):657–659. 3CrossRefPubMed
21.
go back to reference Ozdemir R, Barutcu I, Sezgin AT, Acikgoz N, Ermis N, Metin Esen A, Topal E, Barıskaner E, Ozerol I (2004) Vascular endothelial function and plasma homocysteine levels in Behcet’s disease. Am J Cardiol 94(4):522–525CrossRefPubMed Ozdemir R, Barutcu I, Sezgin AT, Acikgoz N, Ermis N, Metin Esen A, Topal E, Barıskaner E, Ozerol I (2004) Vascular endothelial function and plasma homocysteine levels in Behcet’s disease. Am J Cardiol 94(4):522–525CrossRefPubMed
22.
go back to reference Acikgoz N, Ermiş N, Yağmur J et al (2011) Elevated oxidative stress markers and its relationship with endothelial dysfunction in Behçet disease. Angiology 62(4):296–300CrossRefPubMed Acikgoz N, Ermiş N, Yağmur J et al (2011) Elevated oxidative stress markers and its relationship with endothelial dysfunction in Behçet disease. Angiology 62(4):296–300CrossRefPubMed
23.
go back to reference Balta S, Demirkol S, Celik T, Kucuk U, Unlu M, Arslan Z, Balta I, Iyisoy A, Kocak N, Haqmal H, Yokusoglu M (2013) Association between coronary artery ectasia and neutrophil-lymphocyte ratio. Angiology 64(8):627–632CrossRefPubMed Balta S, Demirkol S, Celik T, Kucuk U, Unlu M, Arslan Z, Balta I, Iyisoy A, Kocak N, Haqmal H, Yokusoglu M (2013) Association between coronary artery ectasia and neutrophil-lymphocyte ratio. Angiology 64(8):627–632CrossRefPubMed
24.
go back to reference Mendoza-Pinto C, Garcia-Carrasco M, Jimenez-Hernandez M et al (2010) Etiopathogenesis of Behcet’s disease. Autoimmun Rev 9:241–245CrossRefPubMed Mendoza-Pinto C, Garcia-Carrasco M, Jimenez-Hernandez M et al (2010) Etiopathogenesis of Behcet’s disease. Autoimmun Rev 9:241–245CrossRefPubMed
25.
go back to reference Balkarli A, Kucuk A, Babur H et al (2015) AB0629 neutrophil/lymphocyte ratio and mean platelet volume in behçet’s disease. Ann Rheum Dis 74:1109CrossRef Balkarli A, Kucuk A, Babur H et al (2015) AB0629 neutrophil/lymphocyte ratio and mean platelet volume in behçet’s disease. Ann Rheum Dis 74:1109CrossRef
26.
go back to reference Ozturk C, Balta S, Balta I, Demirkol S, Celik T, Turker T, Iyisoy A, Eksioglu M (2015) Neutrophil-lymphocyte ratio and carotid-intima media thickness in patients with Behcet disease without cardiovascular involvement. Angiology 66:291–296CrossRefPubMed Ozturk C, Balta S, Balta I, Demirkol S, Celik T, Turker T, Iyisoy A, Eksioglu M (2015) Neutrophil-lymphocyte ratio and carotid-intima media thickness in patients with Behcet disease without cardiovascular involvement. Angiology 66:291–296CrossRefPubMed
Metadata
Title
Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in Behçet’s disease: which and when to use?
Authors
Marwa Hammad
Omaima Zakaria Shehata
Shaimaa Mohamed Abdel-Latif
Amany Mohamed Mohiey El-Din
Publication date
01-10-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 10/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4194-z

Other articles of this Issue 10/2018

Clinical Rheumatology 10/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.